Koers BioLineRx Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
BLRX
IL0011015182
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 14,36 mln. 53,3 mln. 13,35 mln. | Omzet 2025 * | 27,77 mln. 103 mln. 25,81 mln. | Marktkapitalisatie | 54,6 mln. 203 mln. 50,74 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -47 mln. -174 mln. -43,68 mln. | Nettowinst (verlies) 2025 * | -36 mln. -134 mln. -33,46 mln. | EV/omzet 2024 * | 3,8 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,97 x |
K/w-verhouding 2024 * |
-2,28
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,64% |
Recentste transcriptie over BioLineRx Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24-05-09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01-01-09 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24-02-14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01-01-10 |
Aharon Schwartz
CHM | Chairman | 80 | 01-01-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |